Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study
- 359 Downloads
Erythropoietin (Epo) has neurotrophic effects and may be a novel therapeutic agent in the treatment of depression. We have found antidepressant-like effects of Epo on emotional processing and mood in healthy volunteers.
The current study aimed to explore the effects of Epo on the neural processing of emotional information in depressed patients.
Materials and methods
Seventeen patients with acute major depressive disorder were randomised to receive Epo (40,000 IU) or saline iv in a double-blind, parallel-group design. On day 3, we assessed neural responses to positive, negative and neutral pictures during fMRI followed by picture recall after the scan. Mood and blood parameters were assessed at baseline and on day 3.
Epo reduced neural response to negative vs. positive pictures 3 days post-administration in a network of areas including the hippocampus, ventromedial prefrontal and parietal cortex. After the scan, Epo-treated patients showed improved memory compared with those that were given placebo. The effects occurred in the absence of changes in mood or haematological parameters, suggesting that they originated from direct neurobiological actions of Epo.
These findings are similar to the effects of conventional antidepressants and opposite to the negative biases in depression. The central effects of Epo therefore deserve further investigation as a potential antidepressant mechanism.
KeywordsAntidepressant Human Emotion Depression Neuroimaging
We thank Drs. Digby Quested, Susan Shaw, Mary-Jane Attenburrow and Peter Sargent for their help with patient recruitment and Drs. Mike Browning, Danilo Arnone, Sarah McTavish and Matthew Taylor for the medical assistance. The study was supported by the Lundbeck Foundation, Denmark (grant no. 94/04).
- Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, Zhang M, Müller M, Hassouna I, Hannke K, Sperling S, Radyushkin K, El-Kordi A, Schulze L, Ronnenberg A, Wolf F, Brose N, Rhee JS, Zhang W, Ehrenreich H (2008) Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 6:37CrossRefPubMedGoogle Scholar
- Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, Heinz G, Erdag S, Jahn H, Degner D, Ritzen M, Mohr A, Wagner M, Schneider U, Bohn M, Huber M, Czernik A, Pollmächer T, Maier W, Sirén AL, Klosterkötter J, Falkai P, Rüther E, Aldenhoff JB, Krampe H (2007a) Improvement of cognitive function in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12:206–220CrossRefPubMedGoogle Scholar
- Lang PJ, Bradley MM, Cuthbert BN, International Affective Picture System (IAPS) (1997) Technical Manual and Affective Ratings. NIMH Center for the Study of Emotion and Attention 1997. University of Florida, Gainesville FLGoogle Scholar
- Murray CLJ, Lopez AD (1997) Global disability, and the contribution of risk factors. Global Burden of Disease Study. Lancet 49:1439–1442Google Scholar
- Spielberger CD (1983) Manual for the State-Trait Anxiety Inventory STAI. Consulting Psychologists Press, Palo Alto, CAGoogle Scholar
- Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain. Thieme, New YorkGoogle Scholar
- Von Zerssen D, Strain F, Schwartz D (1974) Evaluation of depressive states, especially in longitudinal studies. In: Pichot P (ed) Psychological measurement in psychopharmacology. Modern problems in pharmacopsychiatry. Karger, Basel, pp 189–202Google Scholar
- Williams JMG, Watts FN, MacLeod C, Mathews A (1997) Cognitive psychology and emotional disorders. Wiley, ChichesterGoogle Scholar